PE20060002A1 - Combinaciones antineoplasicas de cci-779 y rituximab - Google Patents
Combinaciones antineoplasicas de cci-779 y rituximabInfo
- Publication number
- PE20060002A1 PE20060002A1 PE2005000263A PE2005000263A PE20060002A1 PE 20060002 A1 PE20060002 A1 PE 20060002A1 PE 2005000263 A PE2005000263 A PE 2005000263A PE 2005000263 A PE2005000263 A PE 2005000263A PE 20060002 A1 PE20060002 A1 PE 20060002A1
- Authority
- PE
- Peru
- Prior art keywords
- rituximab
- cci
- composition
- refers
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE DE TEMSIRULIMUS (CCI-779) CON DOSIS INICIALES ENTRE 25-175 mg ADMINISTRADOS PREFERENTEMENTE POR VIA ORAL Y RITUXIMAB EN DOSIS UNICAS POR VIA INTRAVENOSA EN CONCENTRACIONES DE 10-500 mg/m2. DICHA COMPOSICION, ADMINISTRADA EN CANTIDADES SUBTERAPEUTICAMENTE EFICADES, REDUCE LOS EFECTOS COLATERALES DEL TRATAMIENTO CON RITUXIMAB. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA DE DOSIFICACION UNITARIA SIENDO UTILES EN EL TRATAMIENTO DEL LINFOMA NO HODGKIN
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55212204P | 2004-03-11 | 2004-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20060002A1 true PE20060002A1 (es) | 2006-02-14 |
Family
ID=34964832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005000263A PE20060002A1 (es) | 2004-03-11 | 2005-03-08 | Combinaciones antineoplasicas de cci-779 y rituximab |
Country Status (21)
Country | Link |
---|---|
US (1) | US20050272758A1 (es) |
EP (1) | EP1722817A1 (es) |
JP (1) | JP2007528399A (es) |
KR (1) | KR20070027510A (es) |
CN (1) | CN1929863A (es) |
AR (1) | AR047988A1 (es) |
AU (1) | AU2005221675A1 (es) |
BR (1) | BRPI0508451A (es) |
CA (1) | CA2557005A1 (es) |
CR (1) | CR8571A (es) |
EC (1) | ECSP066835A (es) |
GT (1) | GT200500040A (es) |
IL (1) | IL177565A0 (es) |
NO (1) | NO20064130L (es) |
PA (1) | PA8625801A1 (es) |
PE (1) | PE20060002A1 (es) |
RU (1) | RU2389508C2 (es) |
SG (1) | SG150559A1 (es) |
SV (1) | SV2005002048A (es) |
TW (1) | TW200539869A (es) |
WO (1) | WO2005087265A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
AR046194A1 (es) * | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
CN101155579B (zh) | 2005-02-03 | 2012-10-31 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
JP2006306743A (ja) * | 2005-04-26 | 2006-11-09 | Hamamatsu Photonics Kk | 体液処理方法 |
PT2298815E (pt) | 2005-07-25 | 2015-07-16 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
CN103110948A (zh) * | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
WO2008116163A1 (en) * | 2007-03-22 | 2008-09-25 | Oregon Health & Science University | Therapeutic drug combinations for treatment of b-cell malignancies |
TW200901989A (en) * | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
WO2009126944A1 (en) | 2008-04-11 | 2009-10-15 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
KR20130088908A (ko) | 2008-06-17 | 2013-08-08 | 와이어쓰 엘엘씨 | Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
CN109464445A (zh) | 2008-08-04 | 2019-03-15 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
JP2012508774A (ja) * | 2008-11-13 | 2012-04-12 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Cd37免疫治療薬併用療法およびその使用 |
ES2941894T3 (es) | 2009-04-06 | 2023-05-26 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib contra el cáncer de mama |
US20130028895A1 (en) * | 2011-07-27 | 2013-01-31 | Gerald Wulf | Exosome inhibiting agents and uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
DK1319008T3 (da) * | 2000-09-19 | 2009-02-09 | Wyeth Corp | Vandoplöselige rapamycinestere |
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
US20020198137A1 (en) * | 2001-06-01 | 2002-12-26 | Wyeth | Antineoplastic combinations |
UA78706C2 (en) * | 2001-06-01 | 2007-04-25 | Wyeth Corp | Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
KR20060006058A (ko) * | 2003-04-22 | 2006-01-18 | 와이어쓰 | 항신생물성 배합물 |
AR046194A1 (es) * | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
-
2005
- 2005-03-02 AR ARP050100792A patent/AR047988A1/es unknown
- 2005-03-03 TW TW094106420A patent/TW200539869A/zh unknown
- 2005-03-04 GT GT200500040A patent/GT200500040A/es unknown
- 2005-03-08 PE PE2005000263A patent/PE20060002A1/es not_active Application Discontinuation
- 2005-03-09 CA CA002557005A patent/CA2557005A1/en not_active Abandoned
- 2005-03-09 WO PCT/US2005/007724 patent/WO2005087265A1/en active Application Filing
- 2005-03-09 EP EP05732252A patent/EP1722817A1/en not_active Withdrawn
- 2005-03-09 SG SG200901440-8A patent/SG150559A1/en unknown
- 2005-03-09 RU RU2006130623/14A patent/RU2389508C2/ru not_active IP Right Cessation
- 2005-03-09 CN CNA2005800077977A patent/CN1929863A/zh active Pending
- 2005-03-09 JP JP2007502952A patent/JP2007528399A/ja not_active Withdrawn
- 2005-03-09 AU AU2005221675A patent/AU2005221675A1/en not_active Withdrawn
- 2005-03-09 BR BRPI0508451-2A patent/BRPI0508451A/pt not_active IP Right Cessation
- 2005-03-09 US US11/075,509 patent/US20050272758A1/en not_active Abandoned
- 2005-03-09 KR KR1020067018038A patent/KR20070027510A/ko not_active Application Discontinuation
- 2005-03-10 SV SV2005002048A patent/SV2005002048A/es unknown
- 2005-03-10 PA PA20058625801A patent/PA8625801A1/es unknown
-
2006
- 2006-08-17 IL IL177565A patent/IL177565A0/en unknown
- 2006-08-24 CR CR8571A patent/CR8571A/es not_active Application Discontinuation
- 2006-09-11 EC EC2006006835A patent/ECSP066835A/es unknown
- 2006-09-13 NO NO20064130A patent/NO20064130L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2005087265A8 (en) | 2006-10-05 |
CA2557005A1 (en) | 2005-09-22 |
RU2006130623A (ru) | 2008-04-20 |
BRPI0508451A (pt) | 2007-07-24 |
JP2007528399A (ja) | 2007-10-11 |
IL177565A0 (en) | 2006-12-10 |
TW200539869A (en) | 2005-12-16 |
AR047988A1 (es) | 2006-03-15 |
RU2389508C2 (ru) | 2010-05-20 |
GT200500040A (es) | 2005-10-24 |
CN1929863A (zh) | 2007-03-14 |
ECSP066835A (es) | 2006-11-24 |
US20050272758A1 (en) | 2005-12-08 |
PA8625801A1 (es) | 2006-06-02 |
SG150559A1 (en) | 2009-03-30 |
CR8571A (es) | 2007-02-05 |
KR20070027510A (ko) | 2007-03-09 |
EP1722817A1 (en) | 2006-11-22 |
AU2005221675A1 (en) | 2005-09-22 |
SV2005002048A (es) | 2005-11-04 |
NO20064130L (no) | 2006-10-10 |
WO2005087265A1 (en) | 2005-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20060002A1 (es) | Combinaciones antineoplasicas de cci-779 y rituximab | |
CO6160321A2 (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo | |
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
BRPI0506977A (pt) | composto de tetrahidrocarbolina como agentes anticáncer | |
DK1689724T3 (da) | Quinazolinonforbindelser som anticancermidler | |
AR042051A1 (es) | Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
CO6160236A2 (es) | Inhibidor de quinasa | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
AR086412A1 (es) | Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del sintoma tumores de celulas b | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
AR061887A1 (es) | Una composicion de vacuna contra el dengue | |
CR11418A (es) | Trans-clomifeno para el sindrome metabolico | |
AR061122A1 (es) | Regimen de cladribina para tratar la escleorosis multiple | |
ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
CO6280574A2 (es) | Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia | |
CO5700723A2 (es) | Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca | |
PE20061245A1 (es) | Composiciones para la transmision transmucosa oral de la metformina | |
AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
BRPI0606119B8 (pt) | preparações injetáveis de diclofenaco e seus sais farmaceuticamente aceitáveis | |
AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
PE20130147A1 (es) | Combinacion farmaceutica de teobromina y un agente antitusivo no opioide | |
UY30065A1 (es) | Composiciones farmacéuticas para la erradicación de helicobacter pylori |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |